Status:

COMPLETED

The Use of J-Plasma® for Dermal Resurfacing

Lead Sponsor:

Apyx Medical

Conditions:

Facial Wrinkles

Rhytides

Eligibility:

All Genders

30+ years

Phase:

NA

Brief Summary

This study evaluates the safety and effectiveness of J-Plasma in the reduction of facial wrinkles and rhytides. It is a multi-center, single arm, evaluator-blind prospective study of 55 study subjects...

Detailed Description

The study objective is to demonstrate the safety and efficacy of the J-Plasma system for use in dermal skin resurfacing. This is a multi-center, single arm, evaluator-blind prospective study of 55 st...

Eligibility Criteria

Inclusion

  • Male or female subjects ≥30 years of age.
  • Subject is seeking improvement of facial appearance by reducing facial wrinkles and rhytides.
  • Subject with a facial wrinkle score rating of at least 2 on the FWS as determined by the investigator.
  • Subject with a Fitzpatrick Skin Scale score ≤III.
  • Subject is willing and able to provide written informed consent.
  • Subject is willing and able to comply with protocol requirements, including obtaining study-required images/photos and assessments, and returning for follow-up visits.
  • Subject is willing to release rights to study Sponsor for the use of the photos, including in potential publication.
  • Subject is willing to abstain from other facial cosmetic procedures through the 6 month follow-up visit; examples include, but are not limited to, laser or chemical re-surfacing, dermabrasion, neuromodulator and/or filler injections, aesthetic facial surgery, etc.

Exclusion

  • Subject with a Fitzpatrick Skin Scale score \>III.
  • Subject is pregnant or lactating.
  • Active HSV-1 or diabetes mellitus.
  • Active cut, wound, or infection on the skin of the face.
  • Subject has used, within the past 30 days, Accutane or any medication that can cause dermal hypersensitivity.
  • Subject has a history of autoimmune disease.
  • Subject with a bleeding disorder or who is on blood thinning medication that may be at risk for bleeding.
  • Subject has a known adverse reaction to anesthetics.
  • Subjects with active skin disease of the facial area or known connective tissue disease.
  • Subjects with known susceptibility to keloid formation or hypertrophic scarring.
  • Subjects with present cancerous or pre-cancerous lesions in the area to be treated.
  • Subject who, for any reason, suspects that they will not be able to complete the prescribed follow-up assessment(s);
  • Subject has had concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety and efficacy of the study treatment method.
  • Subject is not willing to release rights to study Sponsor for the use of the photos, including in potential publication.
  • Subject is enrolled in another investigational (drug or device) clinical trial that can interfere with this study's assessments.
  • Subject has undergone a facelift procedure or received facial injections within the past year.

Key Trial Info

Start Date :

January 22 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 16 2018

Estimated Enrollment :

55 Patients enrolled

Trial Details

Trial ID

NCT03286283

Start Date

January 22 2018

End Date

November 16 2018

Last Update

July 27 2022

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Miami Plastic Surgery

Miami, Florida, United States, 33176

2

Institute for Integrated Aesthetics

Sarasota, Florida, United States, 34237

3

Atlanta Dermatology, Vein & Research Center

Alpharetta, Georgia, United States, 30022